Ionis Pharmaceuticals (MEX:IONS) EPS without NRI: MXN-47.75 (TTM As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
67 GF Score
Price MXN1,150.00
GF Value MXN757.76
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals EPS without NRI?

Ionis Pharmaceuticals MEX:IONS 67 EPS without NRI is MXN-47.75 as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 67/100 and a GF Value™ of MXN757.76. The stock has 8 warning signs investors should review. Among 1,170 Biotechnology companies, Ionis Pharmaceuticals ranks worse than 72.05% on this metric.

Ionis Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2026 was MXN-13.25. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-47.75.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Ionis Pharmaceuticals's EPS without NRI or its related term are showing as below:

MEX:IONS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -152   Med: -0.9   Max: 69.4
Current: -0.9

MEX:IONS's 3-Year EPS without NRI Growth Rate is ranked worse than
72.05% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs MEX:IONS: -0.90

Ionis Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was MXN-10.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-36.98.

Ionis Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was MXN-10.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-35.47.


Ionis Pharmaceuticals  (MEX:IONS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ionis Pharmaceuticals EPS without NRI Related Terms


Ionis Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals EPS without NRI Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.78 -55.24 -51.61 -77.74 -52.45

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.32 12.66 -19.54 -27.62 -13.25

MEX:IONS vs EXEL, BBIO, AXSM: EPS without NRI Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's PE Ratio without NRI falls into.


MEX:IONS
67GF Score
Ionis Pharmaceuticals Inc MEX:IONS
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-47.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of MXN-47.75 mean?
Ionis Pharmaceuticals (MEX:IONS) has a EPS without NRI of MXN-47.75 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #843 out of 1170 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Ionis Pharmaceuticals' EPS without NRI too high?
Ionis Pharmaceuticals' current EPS without NRI is MXN-47.75. Based on the distribution chart, Ionis Pharmaceuticals ranks #843 out of 1170 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' EPS without NRI compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #843 out of 1170 companies for EPS without NRI. This places Ionis Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current EPS without NRI is MXN-47.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current EPS without NRI of MXN-47.75. The stock's GF Value™ is MXN757.76, compared to a current price of MXN1,150.00 — trading 51.8% above its estimated fair value. The current EPS without NRI is MXN-47.75. Ionis Pharmaceuticals' overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current EPS without NRI is MXN-47.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 51.8% above its estimated GF Value™ of MXN757.76.

Key valuation signals for MEX:IONS:

  • EPS without NRI: MXN-47.75
  • GF Value™: MXN757.76 vs. price of MXN1,150.00 (51.8% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
67GF Score

Get the complete analysis for MEX:IONS

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN757.76
GF Value